NCT02555371 - Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients | Biotech Hunter

Enrollment

306

Participants

Timeline

Start Date

January 7, 2016

Primary Completion Date

July 24, 2019

Study Completion Date

July 24, 2019

Conditions

Asthma

Interventions

BIOLOGICAL

Mepolizumab 100mg

Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.

DRUG

Placebo

The placebo will be 0.9% sodium chloride solution and will be provided by the study site.

Trial Locations (73)

2305

GSK Investigational Site, New Lambton

5600

GSK Investigational Site, San Rafael

6009

GSK Investigational Site, Nedlands

6504

GSK Investigational Site, New Haven

10367

GSK Investigational Site, Berlin

13915

GSK Investigational Site, Marseille

14068

GSK Investigational Site, Anyang-Si, Gyeonggi-do

14584

GSK Investigational Site, Bucheon-si, Gyeonggi-do

14642

GSK Investigational Site, Rochester

16499

GSK Investigational Site, Suwon-si, Gyeonggi-do

17033

GSK Investigational Site, Hershey

21018

GSK Investigational Site, Vinnytsia

21224

GSK Investigational Site, Baltimore

23552

GSK Investigational Site, Lübeck

27104

GSK Investigational Site, Winston-Salem

27705

GSK Investigational Site, Durham

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

28644

GSK Investigational Site, Cheongju-si, Chungcheongbuk-do

31707

GSK Investigational Site, Albany

34295

GSK Investigational Site, Montpellier

37212

GSK Investigational Site, Nashville

39120

GSK Investigational Site, Magdeburg

49074

GSK Investigational Site, Dnipropetrovsk

54003

GSK Investigational Site, Mykolayiv

55905

GSK Investigational Site, Rochester

59037

GSK Investigational Site, Lille

60596

GSK Investigational Site, Frankfurt am Main

61124

GSK Investigational Site, Kharkiv

61469

GSK Investigational Site, Gwangju

63263

GSK Investigational Site, Neu-Isenburg

63571

GSK Investigational Site, Gelnhausen

75877

GSK Investigational Site, Paris

80206

GSK Investigational Site, Denver

84107

GSK Investigational Site, Murray

90808

GSK Investigational Site, Long Beach

92506

GSK Investigational Site, Riverside

94275

GSK Investigational Site, Le Kremlin-Bicêtre

123182

GSK Investigational Site, Moscow

194354

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

454106

GSK Investigational Site, Chelyabinsk

700115

GSK Investigational Site, Iași

S2000DBS

GSK Investigational Site, Rosario

C1424BSF

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

H2X 3E4

GSK Investigational Site, Montreal

H4J 1C5

GSK Investigational Site, Montreal

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

G1V 4G5

GSK Investigational Site, Québec

296-8602

GSK Investigational Site, Chiba

802-0052

GSK Investigational Site, Fukuoka

811-1394

GSK Investigational Site, Fukuoka

370-0615

GSK Investigational Site, Gunma

319-1113

GSK Investigational Site, Ibaraki

252-0392

GSK Investigational Site, Kanagawa

596-8501

GSK Investigational Site, Osaka

102-0083

GSK Investigational Site, Tokyo

103-0027

GSK Investigational Site, Tokyo

1105 AZ

GSK Investigational Site, Amsterdam

8934 AD

GSK Investigational Site, Leeuwarden

15-044

GSK Investigational Site, Bialystok

30-033

GSK Investigational Site, Krakow

90-153

GSK Investigational Site, Lodz

54-239

GSK Investigational Site, Wroclaw

050159

GSK Investigational Site, Bucharest

656 045

GSK Investigational Site, Barnaul

06973

GSK Investigational Site, Seoul

120/752

GSK Investigational Site, Seoul

03004

GSK Investigational Site, Alicante

08025

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

08208

GSK Investigational Site, Sabadell (Barcelona)